2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
7
Genitourinary
5
Thoracic
4
Other hematologic neoplasm
3
Lymphoid
3
Breast
3
Gynecologic
2
Dermatologic
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Head & Neck
1
Gastrointestinal
1
Conditions
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
Mesothelioma
1
Lung Neoplasms
1
Breast Neoplasms
1
Interventions
Cisplatin
147
pembrolizumab
129
Carboplatin
126
Injections
108
Pemetrexed
99
Paclitaxel
97
Gemcitabine
85
Irinotecan
75
Cyclophosphamide
72
Nivolumab
71
Docetaxel
68
Bevacizumab
59
Oxaliplatin
50
Fluorouracil
50
Capecitabine
48
atezolizumab
46
Leucovorin
42
Etoposide
42
tislelizumab
40
toripalimab
36
fludarabine
32
Drug Therapy
32
Ipilimumab
30
Topotecan
29
durvalumab
28
Vincristine
27
Specimen Handling
27
Early Intervention, Educational
27
Radiotherapy
26
Interviews as Topic
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Valacyclovir
×
Other solid neoplasm
×
Clear all
NCT01997190
2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1
Completed
19 enrolled